

Accepted Article

**HOW DOES COFFEE PREVENT LIVER FIBROSIS?  
BIOLOGICAL PLAUSIBILITY FOR RECENT EPIDEMIOLOGICAL  
OBSERVATIONS**

Jonathan A. Dranoff<sup>1</sup>, Jordan J. Feld<sup>2</sup>, Élise G. Lavoie<sup>1</sup>, and Michel Fausther<sup>1</sup>

<sup>1</sup>Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences; <sup>2</sup>Toronto Western Hospital Liver Center

Address for Correspondence: Jonathan A. Dranoff; University of Arkansas for Medical Sciences; 4301 W. Markham St. mail slot #567; Little Rock AR 72205; email [jdranoff@uams.edu](mailto:jdranoff@uams.edu)

Grant Support: This work was supported by NIH/NIDDK R01 DK076735 to JAD and an American Liver Foundation “Roger L. Jenkins, MD” Postdoctoral Research Fellowship Award to MF.

The published epidemiological data demonstrating an inverse relationship between coffee (and potentially other caffeinated beverage) consumption and liver fibrosis and its downstream complications are weighty and rapidly accumulating. Several excellent recent reviews examine this evidence in great detail (1-3), and the overwhelming conclusion is that this inverse relationship is real – coffee drinking reduces liver fibrosis. Among the strongest studies to support this observation are the findings that, after adjustment for confounders, individuals in the highest quintile of caffeine consumption had less than one third the risk of ALT elevation of those in the lowest quintile (odds ratio (OR) 0.31, 95% CI 0.16-0.61) (4) and, perhaps more importantly, advanced liver fibrosis from chronic liver diseases of various etiologies is associated with reduced coffee and total caffeine consumption (5) with one study showing that the odds of having cirrhosis decreased with increasing daily consumption of coffee in a step-wise manner from an OR of 0.47 (95% CI 0.20-1.10) for patients consuming 1 cup of coffee per day to an OR of 0.16 (95% CI 0.05-0.50) for patients consuming 4 cups per day, compared to lifetime abstainers as the reference (OR 1.0) (6). Demonstrating the clinical significance of coffee consumption, Freedman and colleagues found that among patients with advanced fibrosis, those who consumed no coffee had a risk of hepatic decompensation or hepatocellular carcinoma (HCC) of 11.1 per 100 patient-years compared to just 6.3 per 100 patient-years in those consuming  $\geq 3$  cups of coffee per day, with no beneficial effect seen with tea or other sources of caffeine (7). Coffee consumption has also been shown to be associated with a lower risk of fatty liver disease (8), metabolic syndrome (9), and ultimately hepatocellular carcinoma (10). As a clinician

or scientist interested in the pathogenesis of liver fibrosis, one may very well ask whether these findings are of great value.

Biological plausibility is the concept that an observed epidemiological association is “consistent with existing biological and medical knowledge” (11). This concept has long been considered a cornerstone in attempts to move epidemiological associations, even those that have been replicated on multiple occasions, to a high likelihood of causality (e.g., the now overwhelmingly accepted concept that tobacco smoking causes lung disease (12). Here we provide one of potentially several mechanisms by which coffee/caffeine consumption blocks liver fibrosis – that caffeine inhibits adenosinergic signaling in liver myofibroblasts – with strong hopes of providing biological plausibility for the observed epidemiological associations. We acknowledge fully that other potential mechanisms, such as antioxidant and anti-inflammatory properties of coffee constituents, are of possible importance; however, these concepts are not sufficiently developed at the level of observed science.

The beneficial effects of coffee and caffeine extract against liver fibrosis have been demonstrated by several studies using standard rodent models of experimental liver fibrosis induced by intoxication with dimethylnitrosamine (DMN), carbon tetrachloride (CCl<sub>4</sub>), or thioacetamide (TAA) (13-18). In almost every study, ingestion of coffee blocked toxin-induced liver fibrosis/cirrhosis. Of note, conventional filtered coffee is the form generally used in most of the published studies supporting its protective role. In contrast to the above studies, one report showed that “Turkish style” unfiltered coffee consumption not only lacks any protective effect against CCl<sub>4</sub>-induced liver fibrosis, but rather aggravates CCl<sub>4</sub>-induced hepatotoxicity with significant AST and ALT elevation

(19). Of note, the mechanism(s) underlying these differences was not studied, so more definitive animal experiments are highly warranted.

One mechanism by which coffee may protect against liver fibrosis is via alterations of liver signaling or inflammation. Transforming growth factor- $\beta$  (TGF- $\beta$ ) is a major liver regulatory cytokine secreted in large quantities in standard rodent liver fibrosis models (20). TGF- $\beta$  levels are reduced by coffee and caffeine administration to rats subjected to CCl<sub>4</sub>-, DMN-, and TAA-induced liver fibrosis (13-18). One of the most significant downstream effects of TGF- $\beta$  signaling is the activation of hepatic stellate cells (HSC) (21). In normal liver, HSC are vitamin A-rich, lipid-storing cells present in the space of Disse (22-24). In fibrosing liver, HSC undergo myofibroblastic differentiation and markedly upregulate secretion of extracellular matrix proteins, a process commonly known as HSC activation (24). When liver fibrosis models are performed on rodents exposed to coffee, total liver collagen contents are decreased (13-15, 18).

Activated HSC also secrete matrix metalloproteinases (MMPs), whose activity is essential to maintain the balance between tissue repair and scar formation in fibrotic livers (25). Total liver MMP secretion and activity are decreased by coffee consumption (13, 14). Expression of alpha-smooth muscle actin ( $\alpha$ -SMA) protein is commonly used as a marker of HSC activation in the fibrotic liver (24). In the presence of coffee and caffeine,  $\alpha$ -SMA total liver expression is diminished (13, 16, 18), potentially being indicative of reduced activation of HSCs and disease progression. Altogether, the *in vivo* studies reviewed here show that the anti-fibrotic properties of coffee/caffeine converge at

a point in which HSC activation is diminished, providing biologic plausibility for the human studies cited above.

As noted above, coffee contains myriad chemical substances that could potentially be anti-fibrotic. A number of studies using experimental liver models have specifically addressed this question, by administration of decaffeinated coffee or caffeine solution to animals (13, 16, 19). Non-coffee caffeine was shown to protect liver against fibrosis in both TAA- and CCl<sub>4</sub>-induced liver fibrosis in rats (16, 19, 26). On the other hand, several studies demonstrate that decaffeinated coffee is also protective, but to a lower extent than caffeinated coffee in experimental animals (13, 19). Taken together, it appears that there are noteworthy holes in the animal liver fibrosis literature; there are simply not enough data to make firm conclusions about the relative importance of coffee caffeine content. At present, while it is premature to assume that the major effect of coffee is mediated by caffeine, the preponderance of evidence would suggest that this is the case.

Caffeine and other xanthines, including theophylline, have several known biological targets. These molecules have been characterized as non-selective antagonists of adenosine receptors (AR), inhibitors of phosphodiesterases, antagonists of the GABA<sub>A</sub> receptor, and stimulators of intracellular calcium release (27). While each of these effects is relevant to multiple biological processes, this section focuses on the antagonistic effects of caffeine on adenosine receptors, since this biological effect is relevant to the pathogenesis of liver fibrosis/cirrhosis.

Extracellular adenosine acts via four G-protein-coupled receptors (GPCRs), known as A<sub>1</sub>, A<sub>2a</sub>, A<sub>2b</sub> and A<sub>3</sub> adenosine receptors to induce downstream effects (for

recent review see (28, 29)). The A<sub>1</sub>AR, A<sub>2a</sub>AR and A<sub>3</sub>AR are high-affinity receptors that respond to low concentrations (>10 nM) of extracellular adenosine, while A<sub>2b</sub>AR is a low affinity receptor (>1 μM) thought to be selectively activated in pathological conditions (30). A<sub>1</sub>AR and A<sub>3</sub>AR are coupled to G proteins of the G<sub>i/o</sub> type, leading to downregulation of cAMP-dependent signaling pathways. In contrast, A<sub>2a</sub>AR and A<sub>2b</sub>AR increase the intracellular concentration of cAMP via G<sub>s</sub> coupling. Interestingly, A<sub>2b</sub>AR can also be coupled with G<sub>q</sub> subunit to mobilize intracellular calcium (Ca<sup>2+</sup>).

Experimental evidence of the antagonist effects of caffeine on adenosine receptors was first reported 40 years ago in the heart (31) and in the brain (32). Caffeine is a non-specific antagonist of all adenosine receptors. Specific synthetic agonists and antagonists derived from caffeine and other xanthine compounds have been developed for each AR and are now used as research tools in the studies of their functions, as well as potential therapeutic drugs (27). This is relevant, since specific antagonists of the A<sub>2a</sub>AR inhibit experimental liver fibrosis (26, 33). In contrast, administration of A<sub>1</sub>AR, A<sub>2b</sub>AR and A<sub>3</sub>AR specific antagonists does not significantly impact liver fibrosis progression (26). Thus, the anti-fibrotic effect of caffeine seems to be modulated by its antagonism of the A<sub>2a</sub>AR. In addition, mice lacking A<sub>2a</sub>AR expression are protected against liver fibrosis induced by CCl<sub>4</sub> and TAA (26). A potential role of the A<sub>1</sub>AR in liver fibrosis is more controversial, as A<sub>1</sub>AR deficient mice are also protected against CCl<sub>4</sub>-induced liver fibrosis (34), but administration of the A<sub>1</sub>AR specific antagonist DPCPX has no effect (26).

HSC are well established as primary effector cells during liver fibrosis. Interestingly, human HSC express mRNA for all four adenosine receptors ((35) and

Dranoff JA unpublished data), among which  $A_{2a}$ AR is the most studied as a regulator of HSC function. Mouse HSC express all but  $A_3$ AR receptors (35). Thus, HSC represent a highly plausible cellular target mediating the anti-fibrotic effect of coffee/caffeine acting via adenosine receptor antagonism. Indeed, activation of HSC  $A_{2a}$ AR by extracellular adenosine markedly upregulates collagen secretion (26, 35, 36). Adenosinergic signaling, via  $A_{2a}$ AR activation, redistributes stress fibers and contractile capacity in HSCs (37), likely providing a mechanism for a “stop” signal after cell migration, as evidenced by the observation that  $A_{2a}$ AR activation blocks the chemotaxis of HSC in response to platelet-derived growth factor (PDGF) (35). Finally,  $A_{2a}$ AR activation increased HSC TGF $\beta$  secretion (35) and decreased MMP expression (26). Since all of the mechanisms listed can be blocked by caffeine, blockade of pro-fibrotic adenosinergic signaling in HSC is a reasonable explanation for the antifibrotic effects of coffee.

According to the literature presented here, coffee consumption provides protection against liver fibrosis induced by well-established chemical models. The protective mechanism seems to be mediated primarily by the action of caffeine on HSC  $A_{2a}$ AR. However, there are holes in the literature that will need to be closed. First, since  $CCl_4$  and other pro-fibrotic chemical agents require inflammation to induce fibrosis and cirrhosis, and multiple inflammatory cell types express adenosine receptors (38, 39), the observed effects may be mediated by changes in inflammatory cell function rather than those on HSC function. Second, the animal studies performed have taken only a cursory look at the relative importance of non-caffeine coffee constituents, in part due to methodological limitations. Lastly, animal models of fibrosis are themselves analogues of

human fibrosis-to-cirrhosis progression, but they are not identical. Thus, it is very possible that animal models and studies in isolated HSC will prove useful to identify biological mechanisms, but the relevance to human health will be best tested in studies of human patients.

The progression of liver injury to fibrosis to cirrhosis is a slow but deadly process. The number of North American and European patients with chronic liver disease is increasing, primarily due to steady levels of hepatitis C infection but rapidly expanding levels of fatty liver disease (primarily non-alcoholic). Thus, identification of simple measures that can slow fibrosis and prevent cirrhosis in at-risk patients is critical. Since coffee consumption appears to have salutary effects on human health overall, coffee is an attractive lifestyle measure that patients can take.

Are we ready to “write a prescription for coffee”, as asked by Torres and Harrison in a recent commentary article? (1) Most likely, the answer is yes. Our rationale is as follows. First, there is sufficient evidence to provide biological plausibility for coffee as an anti-fibrotic. Second, coffee (for most individuals) is a pleasant addition to the diet, without profound adverse effects and possibly some other health benefits (again for most individuals). Lastly, other anti-fibrotic treatments are simply lacking; they are in the pipeline, but not yet available clinically.

However, we must face caveats as well. The human studies cited suggest that the most potent observed effects of coffee require the equivalent of four or more cups per day. We are not convinced that most individuals would easily tolerate this. Moreover, if we assume that the anti-fibrotic effects of coffee are mediated by caffeine, then should patients also be offered equivalent “doses” of tea, caffeinated soft drinks, or even caffeine



pills? The latter two do not seem to be consistent with contemporary health practice, and probably for good reason. Thus, at present, we would suggest that any recommendations be limited to coffee (and for reasons cited above, limited to brewed coffee).

Hopefully, the most important effect gained by the observations reviewed here is not the use of coffee as a drug, but rather the generation of testable hypotheses as to the pathogenesis, prevention, and treatment of liver fibrosis and cirrhosis.

Accepted Article

**FIGURE LEGENDS**

**Figure 1. Proposed mechanism for the anti-fibrotic effect of caffeine in chronic liver disease.** Caffeine is a known antagonist of the  $A_{2a}$  adenosinergic receptor expressed on activated hepatic stellate cells and other liver myofibroblasts. Stimulation of the  $A_{2a}$ AR has several downstream pro-fibrogenic effects, including rearrangement of stress fibers, chemotaxis in response to PDGF and other stimuli, and secretion of fibrillar collagen, all of which may be inhibited by caffeine.

## REFERENCES

1. Torres DM, Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. *Gastroenterology* 2013;144:670-672.
2. Masterton GS, Hayes PC. Coffee and the liver: a potential treatment for liver disease? *Eur J Gastroenterol Hepatol* 2010;22:1277-1283.
3. Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. *Aliment Pharmacol Ther* 2007;26:1-8.
4. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. *Gastroenterology* 2005;128:24-32.
5. Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. *Hepatology* 2010;51:201-209.
6. Corrao G, Zambon A, Bagnardi V, D'Amicis A, Klatsky A. Coffee, caffeine, and the risk of liver cirrhosis. *Ann Epidemiol* 2001;11:458-465.
7. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. *Hepatology* 2009;50:1360-1369.
8. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. *Hepatology* 2012;55:429-436.
9. Matsuura H, Mure K, Nishio N, Kitano N, Nagai N, Takeshita T. Relationship between coffee consumption and prevalence of metabolic syndrome among Japanese civil servants. *J Epidemiol* 2012;22:160-166.
10. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. *Clin Gastroenterol Hepatol* 2013;11:1413-1421 e1411.
11. Tygart V. Biological plausibility. [Web article] Edited June 25th, 2013; Accessed December 16th, 2013.  
Available from: [http://en.wikipedia.org/wiki/Biological\\_plausibility](http://en.wikipedia.org/wiki/Biological_plausibility)
12. Hill AB. The Environment and Disease: Association or Causation? *Proc R Soc Med* 1965;58:295-300.
13. Arauz J, Moreno MG, Cortes-Reynosa P, Salazar EP, Muriel P. Coffee attenuates fibrosis by decreasing the expression of TGF-beta and CTGF in a murine model of liver damage. *J Appl Toxicol* 2013;33:970-979.
14. Furtado KS, Prado MG, Aguiar ESMA, Dias MC, Rivelli DP, Rodrigues MA, et al. Coffee and caffeine protect against liver injury induced by thioacetamide in male Wistar rats. *Basic Clin Pharmacol Toxicol* 2012;111:339-347.

15. Moreno MG, Chavez E, Aldaba-Muruato LR, Segovia J, Vergara P, Tsutsumi V, et al. Coffee prevents CCl(4)-induced liver cirrhosis in the rat. *Hepatol Int* 2011;5:857-863.
16. Shim SG, Jun DW, Kim EK, Saeed WK, Lee KN, Lee HL, et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. *J Gastroenterol Hepatol* 2013.
17. Shin JW, Wang JH, Kang JK, Son CG. Experimental evidence for the protective effects of coffee against liver fibrosis in SD rats. *J Sci Food Agric* 2010;90:450-455.
18. Shi H, Dong L, Zhang Y, Bai Y, Zhao J, Zhang L. Protective effect of a coffee preparation (Nescafe pure) against carbon tetrachloride-induced liver fibrosis in rats. *Clin Nutr* 2010;29:399-405.
19. Poyrazoglu OK, Bahcecioglu IH, Ataseven H, Metin K, Dagli AF, Yalniz M, et al. Effect of unfiltered coffee on carbon tetrachloride-induced liver injury in rats. *Inflammation* 2008;31:408-413.
20. Dooley S, ten Dijke P. TGF-beta in progression of liver disease. *Cell Tissue Res* 2012;347:245-256.
21. Hui AY, Friedman SL. Molecular basis of hepatic fibrosis. *Expert Rev Mol Med* 2003;5:1-23.
22. Yokoi Y, Namihisa T, Kuroda H, Komatsu I, Miyazaki A, Watanabe S, et al. Immunocytochemical detection of desmin in fat-storing cells (Ito cells). *Hepatology* 1984;4:709-714.
23. Senoo H, Kojima N, Sato M. Vitamin A-storing cells (stellate cells). *Vitam Horm* 2007;75:131-159.
24. Friedman SL. Evolving challenges in hepatic fibrosis. *Nat Rev Gastroenterol Hepatol* 2010;7:425-436.
25. Roderfeld M, Hemmann S, Roeb E. Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs). *Z Gastroenterol* 2007;45:25-33.
26. Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, et al. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. *Br J Pharmacol* 2006;148:1144-1155.
27. Daly JW. Caffeine analogs: biomedical impact. *Cell Mol Life Sci* 2007;64:2153-2169.
28. Chen JF, Eltzhig HK, Fredholm BB. Adenosine receptors as drug targets--what are the challenges? *Nat Rev Drug Discov* 2013;12:265-286.
29. Fredholm BB, AP IJ, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. *Pharmacol Rev* 2011;63:1-34.
30. Aherne CM, Kewley EM, Eltzhig HK. The resurgence of A2B adenosine receptor signaling. *Biochim Biophys Acta* 2011;1808:1329-1339.
31. Degubareff T, Sleator W, Jr. Effects of Caffeine on Mammalian Atrial Muscle, and Its Interaction with Adenosine and Calcium. *J Pharmacol Exp Ther* 1965;148:202-214.

32. Sattin A, Rall TW. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices. *Mol Pharmacol* 1970;6:13-23.
33. Chiang DJ, Roychowdhury S, Bush K, McMullen MR, Pisano S, Niese K, et al. Adenosine 2A Receptor Antagonist Prevented and Reversed Liver Fibrosis in a Mouse Model of Ethanol-Exacerbated Liver Fibrosis. *PLoS One* 2013;8:e69114.
34. Yang P, Han Z, Chen P, Zhu L, Wang S, Hua Z, et al. A contradictory role of A1 adenosine receptor in carbon tetrachloride- and bile duct ligation-induced liver fibrosis in mice. *J Pharmacol Exp Ther* 2010;332:747-754.
35. Hashmi AZ, Hakim W, Kruglov EA, Watanabe A, Watkins W, Dranoff JA, et al. Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. *Am J Physiol Gastrointest Liver Physiol* 2007;292:G395-401.
36. Che J, Chan ES, Cronstein BN. Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway. *Mol Pharmacol* 2007;72:1626-1636.
37. Sohail MA, Hashmi AZ, Hakim W, Watanabe A, Zipprich A, Groszmann RJ, et al. Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition. *Hepatology* 2009;49:185-194.
38. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat Rev Drug Discov* 2008;7:759-770.
39. Milne GR, Palmer TM. Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. *ScientificWorldJournal* 2011;11:320-339.




Figure 1. Proposed mechanism for the anti-fibrotic effect of caffeine in chronic liver disease. Caffeine is a known antagonist of the  $A_{2a}$  adenosinergic receptor expressed on activated hepatic stellate cells and other liver myofibroblasts. Stimulation of the  $A_{2a}AR$  has several downstream pro-fibrogenic effects, including rearrangement of stress fibers, chemotaxis in response to PDGF and other stimuli, and secretion of fibrillar collagen, all of which may be inhibited by caffeine.

462x314mm (72 x 72 DPI)

Accepted